Future Virology最新文献

{"title":"Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE study.","authors":"Sambhavi Subramanian, Gretja Schnell, Julia di Iulio, Anil K Gupta, Adrienne E Shapiro, Elias H Sarkis, Amanda Lopuski, Amanda Peppercorn, Melissa Aldinger, Christy M Hebner, Andrea L Cathcart","doi":"10.2217/fvl-2023-0146","DOIUrl":"https://doi.org/10.2217/fvl-2023-0146","url":null,"abstract":"<p><p><b>Aim:</b> Sotrovimab is an engineered human monoclonal antibody that binds a conserved region of the SARS-CoV-2 spike protein. The COMET-ICE phase III study evaluated sotrovimab for treatment of mild to moderate COVID-19 in nonhospitalized participants with ≥1 risk factor for severe disease progression. <b>Materials & methods:</b> We evaluated the presence of circulating SARS-CoV-2 variants of concern or interest (VOCs/VOIs) and characterized the presence of baseline, post-baseline and emergent amino acid substitutions detected in the epitope of sotrovimab in SARS-CoV-2. <b>Results:</b> None of the sotrovimab-treated participants with baseline epitope substitutions, and 1 of 48 sotrovimab-treated participants with post-baseline epitope substitutions, met the primary clinical endpoint for progression. <b>Conclusion:</b> Overall, progression was not associated with identified VOC/VOI or the presence of epitope substitutions in sotrovimab-treated participants.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10705769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138801391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genotoxicity: a neglected but potentially critical aspect of adenoviral COVID-19 vaccines","authors":"Alireza Mardomi, Tahoora Mousavi, Farahnoosh Farnood, Hamid Tayebi Khosroshahi","doi":"10.2217/fvl-2023-0013","DOIUrl":"https://doi.org/10.2217/fvl-2023-0013","url":null,"abstract":"Future VirologyAhead of Print EditorialFree AccessGenotoxicity: a neglected but potentially critical aspect of adenoviral COVID-19 vaccinesAlireza Mardomi, Tahoora Mousavi, Farahnoosh Farnood & Hamid Tayebi KhosroshahiAlireza Mardomi https://orcid.org/0000-0001-8422-8448Department of Medical Laboratory Sciences & Microbiology, Faculty of Medical Sciences, Tabriz Medical Sciences, Islamic Azad University, Tabriz, IranSearch for more papers by this author, Tahoora Mousavi https://orcid.org/0000-0003-2505-370XMolecular & Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, IranSearch for more papers by this author, Farahnoosh Farnood https://orcid.org/0000-0002-1199-6881Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, IranSearch for more papers by this author & Hamid Tayebi Khosroshahi *Author for correspondence: Tel.: (+98)9146514509; E-mail Address: drtayebikh@yahoo.comhttps://orcid.org/0000-0002-1131-0413Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, IranSearch for more papers by this authorPublished Online:18 Oct 2023https://doi.org/10.2217/fvl-2023-0013AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail Keywords: adenoviral vaccinesCOVID-19genome integrationmutagenesisSARS-CoV-2A prophylactic immunization against the disease COVID-19, caused by the SARS-CoV-2 virus, can be achieved through vaccination [1]. Vaccination programs have had a remarkable impact on the control of the COVID-19 burden with reports of greater than 90% reductions in mortality rate observed in vaccinated individuals of all ages and reductions in hospitalization by 71–87% [2], though it should be noted that the efficacies of different vaccines against variants of SARS-CoV-2 are variable [1]. However, the long-term safety of COVID-19 vaccines may have been overlooked as a result of the immediacy of the pandemic. Some short-term side effects of the vaccines have gradually become evident; apart from general side effects such as fatigue, headaches, muscle pain and chills, COVID-19 vaccination has been shown to trigger the development of various autoantibodies associated with autoimmune diseases including IgA nephropathy and autoimmune vasculitis [3,4]. Adenoviral-based vaccines are one type of vaccine platform that has been developed for COVID-19 vaccination and warrants further investigation for their potential long-term side effects. These vaccines use a viral vector to deliver a genetic sequence encoding an immunogenic antigen into host cells to elicit transient antigen expression and a prophylactic immune response, but some reports suggest that they may have the potential for genome integration.Viruses have been harnessed as gene-delivery tools in genetic engineering for their biological functions and, while there are also non-viral gene-delivery approaches, viral vectors are known as the most efficient to","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135823841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiviral attributes of bee venom as a possible therapeutic approach against SARS-CoV-2 infection.","authors":"Soumik Goswami, Jayita Pal Chowdhury","doi":"10.2217/fvl-2023-0127","DOIUrl":"https://doi.org/10.2217/fvl-2023-0127","url":null,"abstract":"<p><p>The unprecedented scale of the SARS-CoV-2 pandemic has driven considerable investigation into novel antiviral treatments since effective vaccination strategies cannot completely eradicate the virus. Apitherapy describes the medicinal use of bee venom, which may be an effective treatment against SARS-CoV-2 infection. Bee venom contains chemicals that are antimicrobial and stimulate the immune system to counteract viral load. The present review focuses on the use of bee venom as a possible treatment for COVID-19 and reviews studies on the pharmacodynamics of bee venom.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134648780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>In silico</i> identification of deep-sea fungal alkaloids as potential inhibitors of SARS-CoV-2, Delta and Omicron spikes.","authors":"Abdullah R Alanzi, Mohammad K Parvez, Mohammed S Al-Dosari","doi":"10.2217/fvl-2023-0102","DOIUrl":"10.2217/fvl-2023-0102","url":null,"abstract":"<p><p><b>Aim:</b> Virtual screening of deep-sea fungal metabolites against SARS-CoV-2 Delta and Omicron spikes as potential antivirals. <b>Materials & methods:</b> Deep-sea fungal alkaloids (n ≥ 150) were evaluated against SARS-CoV-2, Delta and Omicron spikes, using various <i>in silico</i> approaches, including Admet scores, physiochemical properties, molecular docking (MD) and MD simulation (150 ns). <b>Results:</b> The test alkaloids complied with Admet scores and physiochemical properties within acceptable ranges, and followed Lipinski's rule of five. Of these, <i>Cladosporium sphaerospermum</i>-derived cladosin K (tetramate alkaloid) for SARS-CoV-2, <i>Cystobasidium laryngis</i>-derived saphenol (phenazine alkaloid) for Delta and <i>Chaetomium globosum</i>-derived chaetoglobosin E (quinoline alkaloid) for Omicron were identified as potential spike-inhibitors. <b>Conclusion:</b> Our data therefore, strongly warrants further experimental validations of cladosin K, saphenol and chaetoglobosin E, especially against the Omicron and Delta spikes.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71432221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY).","authors":"Arantxa Horga, Rebecca Saenz, Gürdal Yilmaz, Abraham Simón-Campos, Keith Pietropaolo, William J Stubbings, Neil Collinson, Laura Ishak, Barbara Zrinscak, Bruce Belanger, Catherine Granier, Kai Lin, Aeron C Hurt, Xiao-Jian Zhou, Steffen Wildum, Janet Hammond","doi":"10.2217/fvl-2023-0115","DOIUrl":"10.2217/fvl-2023-0115","url":null,"abstract":"<p><p><b>Aim:</b> This phase III study assessed the efficacy/safety/antiviral activity/pharmacokinetics of bemnifosbuvir, a novel, oral nucleotide analog to treat COVID-19. <b>Patients & methods:</b> Outpatient adults/adolescents with mild-to-moderate COVID-19 were randomized 2:1 to bemnifosbuvir/placebo. Time to symptom alleviation/improvement (primary outcome), risk of hospitalization/death, viral load and safety were evaluated. <b>Results:</b> Although the study was discontinued prematurely and did not meet its primary end point, bemnifosbuvir treatment resulted in fewer hospitalizations (71% relative risk reduction), COVID-19-related medically attended hospital visits, and COVID-19-related complications compared with placebo. No reduction in viral load was observed. The proportion of patients with adverse events was similar; no deaths occurred. <b>Conclusion:</b> Bemnifosbuvir showed hospitalization reduction in patients with variable disease progression risk and was well tolerated. <b>Clinical Trial Registration</b>: NCT04889040 (ClinicalTrials.gov).</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71480363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of a risk prediction model for COVID-19: the PERIL prospective cohort study.","authors":"Shahd A Mohammedain, Saif Badran, AbdelNaser Y Elzouki, Halla Salim, Ayesha Chalaby, Mya Siddiqui, Yehia Y Hussein, Hanan Abdul Rahim, Lukman Thalib, Mohammed Fasihul Alam, Daoud Al-Badriyeh, Sumaya Al-Maadeed, Suhail Ar Doi","doi":"10.2217/fvl-2023-0036","DOIUrl":"https://doi.org/10.2217/fvl-2023-0036","url":null,"abstract":"<p><p><b>Aim:</b> This study aims to perform an external validation of a recently developed prognostic model for early prediction of the risk of progression to severe COVID-19. <b>Patients & methods/materials:</b> Patients were recruited at their initial diagnosis at two facilities within Hamad Medical Corporation in Qatar. 356 adults were included for analysis. Predictors for progression of COVID-19 were all measured at disease onset and first contact with the health system. <b>Results:</b> The C statistic was 83% (95% CI: 78%-87%) and the calibration plot showed that the model was well-calibrated. <b>Conclusion:</b> The published prognostic model for the progression of COVID-19 infection showed satisfactory discrimination and calibration and the model is easy to apply in clinical practice.d.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134648781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of human papillomavirus type 197 genome in non-melanoma skin cancer and adjacent non-tumoral skin margins","authors":"Zeinab Vosough, Farzin Sadeghi, G. Kamrani, A. Hasanzadeh, Mohammad Ranaee","doi":"10.2217/fvl-2023-0022","DOIUrl":"https://doi.org/10.2217/fvl-2023-0022","url":null,"abstract":"Aim: We aimed to investigate the presence of human papillomavirus type 197 (HPV197) in patients with cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). Materials & methods: 58 formalin-fixed paraffin-embedded tissue samples, including 12 SCC and 46 BCC and the adjacent non-tumoral skin of the same patient were analyzed for the presence of HPV197E6 gene, using a quantitative real-time PCR assay. Results: The HPV197E6 gene was identified in 12 tumor samples (7 BCC and 5 SCC), but not in the control group. Conclusion: Based on these results, a high copy number of HPV197E6 gene provides additional support for the role of HPV197 in skin cancer.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47928648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The first evidence of Seoul hantavirus, hepatitis E virus and rabies virus in Rattus norvegicus in Tehran, Iran","authors":"T. Azimi, Sina Nasrollahian, S. Sabour, Nahal Hadi, L. Azimi, N. Rahbarian, A. Karimi, F. Fallah, Roxana Mansour-Ghanaie, S. Hoseini-Alfatemi, S. A. Fahimzad","doi":"10.2217/fvl-2023-0047","DOIUrl":"https://doi.org/10.2217/fvl-2023-0047","url":null,"abstract":"Aim: The present study aimed to investigate the frequency of Seoul hantavirus (SEOV), Hepatitis E and rabies viruses in Norway rats in Tehran, Iran. Methods: With the aid of a rat ELISA kit, the we identified specific IgG antibodies against the Rabies virus. The presence of SEOV and HEV was determined using an SYBR Green-based real-time PCR assay. Results: 1% of the R. norvegicus carried the rabies virus. HEV was associated with R. norvegicus obtained from the south of Tehran with the highest frequency (35%). 12% of tests for SEOV were positive. Conclusion: The findings highlight the importance of putting in place rodent control programs and avoiding interaction with rodent populations in urban settings.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42547487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of an in vitro model to study hepatitis C virus-induced fibrosis","authors":"Bisma Rauff, Mehdi Ramezani-Moghadam, Enoch S. E. Tay, Jacob George, M. Douglas","doi":"10.2217/fvl-2022-0206","DOIUrl":"https://doi.org/10.2217/fvl-2022-0206","url":null,"abstract":"Aim: To investigate the mechanism of liver fibrosis in chronic hepatitis C virus (HCV) infection we developed an in vitro model. Methods: Huh7 cells were transfected with HCV (JFH1 or Jc1) or sub-genomic replicons and expression of pro-fibrotic cytokines determined by qPCR. Media from infected cells was transferred onto LX2 cells or primary rat stellate cells and expression of pro-fibrotic genes measured by qPCR. Results: Replication competent HCV, but not sub-genomic replicons, induced expression of TGF-β1 and CTGF. Supernatant from infected cells induced α-SMA and COL1A1 expression and stellate cell migration, confirming functional activation. Conclusion: Infected cells produce pro-fibrogenic cytokines TGF-β1 and CTGF and activate stellate cells. This mechanism could be targeted to prevent or treat HCV-induced fibrosis.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":"20 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68215671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yellow fever: is Asia bound to encounter the virus?","authors":"Baijayantimala Mishra, Sutapa Rath, Monalisa Mohanty, Prabhudutta Mamidi","doi":"10.2217/fvl-2023-0128","DOIUrl":"https://doi.org/10.2217/fvl-2023-0128","url":null,"abstract":"Future VirologyAhead of Print EditorialYellow fever: is Asia bound to encounter the virus?Baijayantimala Mishra, Sutapa Rath, Monalisa Mohanty & Prabhudutta MamidiBaijayantimala Mishra *Author for correspondence: Tel.: +91 943 888 4121; E-mail Address: bmishramicro@gmail.comhttps://orcid.org/0000-0002-2604-6678Department of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, 751019, Odisha, IndiaSearch for more papers by this author, Sutapa Rath https://orcid.org/0000-0002-0790-1448Department of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, 751019, Odisha, IndiaSearch for more papers by this author, Monalisa Mohanty https://orcid.org/0000-0003-3940-1998Department of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, 751019, Odisha, IndiaSearch for more papers by this author & Prabhudutta Mamidi https://orcid.org/0000-0002-0187-571XDepartment of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, 751019, Odisha, IndiaSearch for more papers by this authorPublished Online:8 Sep 2023https://doi.org/10.2217/fvl-2023-0128AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: aedes mosquitoAfricaarbovirusAsiatransmissionyellow feverPapers of special note have been highlighted as: • of interest; •• of considerable interestReferences1. Kallas EG, Wilder-Smith A. Managing severe yellow fever in the intensive care: lessons learnt from Brazil. J. Travel Med. 26(5), taz043 (2019). • Paper that describes the clinical spectrums of yellow fever.Crossref, Medline, Google Scholar2. Ho YL, Joelsons D, Leite GFC et al. Severe yellow fever in Brazil: clinical characteristics and management. J. Travel Med. 26(5), taz040 (2019). • A study that described the clinical management of severe yellow fever infection.Crossref, Medline, Google Scholar3. Cunha MDP, Duarte-Neto AN, Pour SZ et al. Phylogeographic patterns of the yellow fever virus around the metropolitan region of São Paulo, Brazil, 2016–2019. PLOS Negl. Trop. Dis. 16(9), e0010705 (2022).Crossref, Medline, CAS, Google Scholar4. Rodríguez-Morales AJ, Bonilla-Aldana DK, Suárez JA et al. Yellow fever reemergence in Venezuela - Implications for international travellers and Latin American countries during the COVID-19 pandemic. Travel Med. Infect. Dis. 44, 102192 (2021). • Article on importance of immunization coverage and optimization of surveillance system for populations at risk of yellow fever.Crossref, Medline, CAS, Google Scholar5. Gardner CL, Ryman KD. Yellow fever: a reemerging threat. Clin. Lab. Med. 30(1), 237–260 (2010).Crossref, Medline, Google Scholar6. Gubler DJ. Pandemic yellow fever: a potential threat to global health via travellers. J. Travel Med. 25(1), (2018). •• One of the earliest paper emphasising on the pandemic potential of yellow fever.Crossref, Medline, Google Scholar7. Song R, Guan S, Le","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136298523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}